12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Dyax, taiba Pharma sales and marketing update

Dyax granted taiba's taiba ME (Dubai, UAE) exclusive rights to market Kalbitor ecallantide to treat hereditary angioedema (HAE) in the Middle East, including Saudi Arabia, UAE, Oman, Bahrain, Qatar, Kuwait, Libya and Iran. Dyax said the...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >